---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-106611"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:38:12.703344+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Korro Bio partners with Novo Nordisk for up to $530M in RNA editing deal for cardiometabolic targets

## Summary
- Up to $530M in upfront, development, and commercial milestone payments plus tiered royalties and R&D funding.
- Upfront fee of $10M for first target; potential additional upfront for second target if nominated.
- Korro grants exclusive worldwide license to Novo Nordisk for two undisclosed cardiometabolic targets using OPERA platform.
- Korro responsible for preclinical development; Novo Nordisk may advance programs through clinical studies.
- Deal allows Korro to retain internal pipeline focus while expanding RNA editing to high-prevalence diseases.

## SEC filing metadata
- accession: 0000950170-24-106611
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024106611/0000950170-24-106611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024106611/krro-20240913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-106611
- JSON: https://secwatch.observer/filing/0000950170-24-106611.json
- Plain text: https://secwatch.observer/filing/0000950170-24-106611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.